Readystate Asset Management LP Eli Lilly & CO Call Options Transaction History

Readystate Asset Management LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$724.87 - $909.04 $18 Million - $22.5 Million	-24,800 Reduced 96.5%	900 $815 Million
Q1 2024 May 10, 2024	BUY	$592.2 - $792.28 $9.53 Million - $12.8 Million	16,100 Added 167.71%	25,700 $20 Billion
Q4 2023 Feb 14, 2024	BUY	$525.19 - $619.13 $5.04 Million - $5.94 Million	9,600 New	9,600 $5.6 Billion
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $279,567 - $328,338	900 New	900 $309 Million

3,912

765M

6.35M

7.95M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $788B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Readystate Asset Management LP with notifications on news.